Overall, anti-IL-12/23 and anti-IL-23 agents provide an effective new option for moderate-to-severe IBD in patients who fail or are intolerant to anti-TNF therapy, and future generations of anti-IL drugs targeting finer subunits or downstream signaling will further promote precision and personalized treatment. This evidence concerns the gene TNF and inflammatory bowel disease.